Profusa (PFSA) and The Competition Financial Review
by Jessica Moore · The Cerbat GemProfusa (NASDAQ:PFSA – Get Free Report) is one of 27 publicly-traded companies in the “Surgical, Medical, And Dental Instruments And Supplies” industry, but how does it compare to its rivals? We will compare Profusa to related businesses based on the strength of its valuation, analyst recommendations, institutional ownership, earnings, profitability, dividends and risk.
Profitability
This table compares Profusa and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Profusa | N/A | N/A | -880.32% |
| Profusa Competitors | -569.68% | -123.14% | -53.62% |
Analyst Ratings
This is a summary of recent ratings and target prices for Profusa and its rivals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Profusa | 1 | 0 | 0 | 0 | 1.00 |
| Profusa Competitors | 80 | 82 | 163 | 7 | 2.29 |
As a group, “Surgical, Medical, And Dental Instruments And Supplies” companies have a potential upside of 54.99%. Given Profusa’s rivals stronger consensus rating and higher probable upside, analysts clearly believe Profusa has less favorable growth aspects than its rivals.
Institutional & Insider Ownership
9.8% of Profusa shares are owned by institutional investors. Comparatively, 19.3% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are owned by institutional investors. 11.4% of Profusa shares are owned by insiders. Comparatively, 19.9% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares Profusa and its rivals revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Profusa | N/A | -$8.71 million | -0.01 |
| Profusa Competitors | $61.19 million | -$27.52 million | 1.49 |
Profusa’s rivals have higher revenue, but lower earnings than Profusa. Profusa is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Risk and Volatility
Profusa has a beta of 0.02, indicating that its stock price is 98% less volatile than the S&P 500. Comparatively, Profusa’s rivals have a beta of 1.80, indicating that their average stock price is 80% more volatile than the S&P 500.
Summary
Profusa rivals beat Profusa on 10 of the 13 factors compared.
Profusa Company Profile
NorthView Acquisition Corporation does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It also intends to focus its search on businesses that are focused on healthcare sector. The company was incorporated in 2021 and is based in New York, New York. NorthView Acquisition Corporation is a subsidiary of NorthView Sponsor I, LLC.